

**REMARKS**

Applicant has amended the title and specification to conform to U.S. format.


The claims have been amended to avoid multiple dependencies and to improve the formatting thereby placing the application in better condition for examination and allowance.

If any additional amendments or changes are necessary, the Examiner is respectfully requested to contact applicant's attorney at the telephone number indicated below.

Respectfully submitted,

KAZUYA HOSOKAWA

By

  
Richard C. Woodbridge  
Attorney for Applicant  
Reg. No. 26,423

Woodbridge & Associates, P.C.  
P.O. Box 592  
Princeton, NJ 08542-0592

Tel (609) 924-3773  
Fax (609) 924-1811

cc: Hatta & Associates

Marked Up Copy

-- 3. A substance according to claim 1 [or claim 2,] wherein said substance is formed by anhydridizing the active serine residue site of the activated blood coagulation factor possessing an active serine residue. --

-- 7. A method for the production of a substance [set forth in any of claims 1 – 6,] capable of inhibiting a reaction between an activated blood coagulating factor and a substrate thereof by binding itself to said substrate in competition with said activated blood coagulating factor characterized by performing the following steps:

(1) a step of causing an active serine residue site of an activated blood coagulation factor possessing an active serine residue to react with a synthetic inhibitor,

(2) a step of performing an alkali treatment at a pH value in the range of 11.0 – 13.5, and

(3) a step of performing collection in the order mentioned above sequentially and allowing at least the step of performing collection to proceed with permitting coexistence of at least one compound selected from the group consisting of polyhydric alcohols and saccharides with a salt or an amphoteric electrolyte. –

-- 8. A blood coagulation factor adsorbent [having] including a substance set forth in [any of] claim[s] 1 [- 6] fixed on a carrier. --